Patents by Inventor HEIKE PETRUL

HEIKE PETRUL has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20170226081
    Abstract: The present invention relates to chemical compounds that selectively inhibit glucose transporter 1 (GLUT1), to methods of preparing said compounds, to pharmaceutical compositions and combinations comprising said compounds, to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease, as well as to intermediate compounds useful in the preparation of said compounds.
    Type: Application
    Filed: July 22, 2015
    Publication date: August 10, 2017
    Applicant: Bayer Pharma Aktiengesellschaft
    Inventors: Bernd BUCHMANN, Iring HEISLER, Thomas MÜLLER, Arwed CLEVE, Mélanie HÉROULT, Roland NEUHAUS, Heike PETRUL, Maria QUANZ-SCHÖFFEL
  • Publication number: 20170210738
    Abstract: The present invention relates to chemical compounds of formula (I) that selectively inhibit glucose transporter 1 (GLUT1), to methods of preparing said compounds, to pharmaceutical compositions and combinations comprising said compounds, to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease, as well as to intermediate compounds useful in the preparation of said compounds.
    Type: Application
    Filed: July 22, 2015
    Publication date: July 27, 2017
    Applicant: Bayer Pharma Aktiengesellschaft
    Inventors: Bernd BUCHMANN, Iring HEISLER, Thomas MÜLLER, Arwed CLEVE, Melanie HEROULT, Roland NEUHAUS, Heike PETRUL, Maria QUANZ-SCHÖFFEL
  • Publication number: 20170037028
    Abstract: The present invention relates to chemical compounds that selectively inhibit glucose transporter 1 (GLUT1), to methods of preparing said compounds, to pharmaceutical compositions and combinations comprising said compounds, to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease, as well as to intermediate compounds useful in the preparation of said compounds.
    Type: Application
    Filed: December 16, 2014
    Publication date: February 9, 2017
    Inventors: Iring HEISLER, Thomas MÜLLER, Holger SIEBENEICHER, Bernd BUCHMANN, Arwed CLEVE, Judith GÜNTHER, Marcus KOPPITZ, Melanie HEROULT, Roland NEUHAUS, Heike PETRUL, Maria QUANZ-SCHÖFFEL
  • Publication number: 20160193359
    Abstract: The present application relates to new binder-drug conjugates (ADCs) of N,N-dialkylauristatins that are directed against the target C4.4a, to active metabolites of these ADCs, to processes for preparing these ADCs, to the use of these ADCs for treating and/or preventing illnesses, and also to the use of these ADCs for producing medicaments for treating and/or preventing illnesses, more particularly hyperproliferative and/or angiogenic diseases such as, for example, cancer diseases. Such treatments may be practised as a monotherapy or else in combination with other medicaments or further therapeutic measures.
    Type: Application
    Filed: February 24, 2016
    Publication date: July 7, 2016
    Applicant: SEATTLE GENETICS, INC.
    Inventors: Hans-Georg LERCHEN, Lars LINDEN, Sherif EL SHEIKH, Jörg WILLUDA, Charlotte C. KOPITZ, Joachim SCHUHMACHER, Simone GREVEN, Christoph MAHLERT, Beatrix STELTE-LUDWIG, Sven GOLFIER, Rudolf BEIER, Iring HEISLER, Axel HARRENGA, Karl-Heinz THIERAUCH, Sandra BRUDER, Heike PETRUL, Hannah Jörißen, Sandra BORKOWSKI
  • Publication number: 20150246136
    Abstract: The present patent application relates to novel binder-drug conjugates (ADCs) of N,N-dialkylauristatins directed against the target epidermal growth factor receptor (EGFR, gene ID 1956), effective metabolites of these ADCs, methods for producing these ADCs, use of these ADCs for treatment and or prevention of diseases as well as the use of these ADCs to produce pharmaceutical drugs for treatment and/or prevention of diseases, in particular hyperproliferative and/or angiogenic diseases such as cancer, for example. Such treatments may be administered as monotherapy or in combination with other pharmaceutical drugs or other therapeutic measures.
    Type: Application
    Filed: May 11, 2015
    Publication date: September 3, 2015
    Applicant: SEATTLE GENETICS, INC.
    Inventors: Hans-Georg LERCHEN, Lars LINDEN, Sherif El SHEIKH, Jörg WILLUDA, Charlotte C. KOPITZ, Joachim SCHUHMACHER, Simone GREVEN, Christoph MAHLERT, Beatrix STELTE-LUDWIG, Sven GOLFIER, Rudolf BEIER, Iring HEISLER, Axel HARRENGA, Karl-Heinz THIERAUCH, Sandra BRUDER, Heike PETRUL, Hannah JÖRISSEN, Sandra BORKOWSKI
  • Patent number: 8992932
    Abstract: The present application relates to new binder-drug conjugates (ADCs) of N,N-dialkylauristatins that are directed against the target C4.4a, to active metabolites of these ADCs, to processes for preparing these ADCs, to the use of these ADCs for treating and/or preventing illnesses, and also to the use of these ADCs for producing medicaments for treating and/or preventing illnesses, more particularly hyperproliferative and/or angiogenic diseases such as, for example, cancer diseases. Such treatments may be practiced as a monotherapy or else in combination with other medicaments or further therapeutic measures.
    Type: Grant
    Filed: October 20, 2012
    Date of Patent: March 31, 2015
    Assignee: Seattle Genetics, Inc.
    Inventors: Hans-Georg Lerchen, Lars Linden, Sherif El Sheikh, Jörg Willuda, Charlotte Christine Kopitz, Joachim Schuhmacher, Simone Greven, Christoph Mahlert, Beatrix Stelte-Ludwig, Sven Golfier, Rudolf Beier, Iring Heisler, Axel Harrenga, Karl-Heinz Thierauch, Sandra Bruder, Heike Petrul, Hannah Jöriβen, Sandra Borkowski
  • Publication number: 20150030618
    Abstract: The present application relates to new binder-drug conjugates (ADCs) of N,N-dialkylauristatins that are directed against the target C4.4a, to active metabolites of these ADCs, to processes for preparing these ADCs, to the use of these ADCs for treating and/or preventing illnesses, and also to the use of these ADCs for producing medicaments for treating and/or preventing illnesses, more particularly hyperproliferative and/or angiogenic diseases such as, for example, cancer diseases. Such treatments may be practised as a monotherapy or else in combination with other medicaments or further therapeutic measures.
    Type: Application
    Filed: May 5, 2014
    Publication date: January 29, 2015
    Applicant: SEATTLE GENETICS, INC.
    Inventors: Hans-Georg LERCHEN, Lars Linden, Sherif El Sheikh, Jörg Willuda, Charlotte C. Kopitz, Joachim Schuhmacher, Simone Greven, Christoph Mahlert, Beatrix Stelte-Ludwig, Sven Golfier, Rudolf Beier, Iring Heisler, Axel Harrenga, Karl-Heinz Thierauch, Sandra Bruder, Heike Petrul, Hannah Jörissen, Sandra Borkowski
  • Publication number: 20140127240
    Abstract: The present patent application relates to novel binder-drug conjugates (ADCs) of N,N-dialkylauristatins directed against the target epidermal growth factor receptor (EGFR, gene ID 1956), effective metabolites of these ADCs, methods for producing these ADCs, use of these ADCs for treatment and or prevention of diseases as well as the use of these ADCs to produce pharmaceutical drugs for treatment and/or prevention of diseases, in particular hyperproliferative and/or angiogenic diseases such as cancer, for example. Such treatments may be administered as monotherapy or in combination with other pharmaceutical drugs or other therapeutic measures.
    Type: Application
    Filed: April 20, 2012
    Publication date: May 8, 2014
    Applicants: Bayer Pharma Aktiengesellschaft, Bayer Intellectual Property GmbH
    Inventors: Hans-Georg Lerchen, Lars Linden, Sherif El Sheikh, Jörg Willuda, Charlotte C. Kopitz, Joachim Schuhmacher, Simone Greven, Christoph Mahlert, Beatrix Stelte-Ludwig, Sven Golfier, Rudolf Beier, Iring Heisler, Axel Harrenga, Karl-Heinz Thierauch, Sandra Bruder, Heike Petrul, Hannah Jörißen, Sandra Brokowski
  • Publication number: 20130122024
    Abstract: The present application relates to new binder-drug conjugates (ADCs) of N,N-dialkylauristatins that are directed against the target mesothelin, to active metabolites of these ADCs, to processes for preparing these ADCs, to the use of these ADCs for treating and/or preventing illnesses, and also to the use of these ADCs for producing medicaments for treating and/or preventing illnesses, more particularly hyperproliferative and/or angiogenic diseases such as, for example, cancer diseases. Such treatments may be practised as a monotherapy or else in combination with other medicaments or further therapeutic measures.
    Type: Application
    Filed: April 20, 2012
    Publication date: May 16, 2013
    Applicant: Bayer Intellectual Property GmbH
    Inventors: Hans-Georg LERCHEN, Beatrix STELTE-LUDWIG, Sven GOLFIER, Charlotte Christine KOPITZ, Rudolf BEIER, Sherif EL SHEIKH, Iring HEISLER, Axel HARRENGA, Karl-Heinz THIERAUCH, Joachim SCHUHMACHER, Sandra BRUDER, Simone GREVEN, Lars LINDEN, Jörg WILLUDA, Christoph MAHLERT, Heike PETRUL, Hannah JÖRIßEN, Sandra Borkowski
  • Publication number: 20130066055
    Abstract: The present application relates to new binder-drug conjugates (ADCs) of N,N-dialkylauristatins that are directed against the target C4.4a, to active metabolites of these ADCs, to processes for preparing these ADCs, to the use of these ADCs for treating and/or preventing illnesses, and also to the use of these ADCs for producing medicaments for treating and/or preventing illnesses, more particularly hyperproliferative and/or angiogenic diseases such as, for example, cancer diseases. Such treatments may be practised as a monotherapy or else in combination with other medicaments or further therapeutic measures.
    Type: Application
    Filed: April 20, 2012
    Publication date: March 14, 2013
    Applicant: Bayer Intellectual Property GmbH
    Inventors: Hans-Georg Lerchen, Lars Linden, Sherif El Sheikh, Jörg Willuda, Charlotte Christine Kopitz, Joachim Schuhmacher, Simone Greven, Christoph Mahlert, Beatrix Stelte-Ludwig, Sven Golfier, Rudolf Beier, Iring Heisler, Axel Harrenga, Karl-Heinz Thierauch, Sandra Bruder, Heike Petrul, Hannah Jörissen, Sandra Borkowski
  • Publication number: 20090137002
    Abstract: The invention concerns antibodies and antibody fragments, specifically recognising the EphB4 receptor comprising heavy chains and light chain, comprising light and heavy CDR's, and their use as medicament for the treatment of pathological angiogenesis, in particular cancer therapy.
    Type: Application
    Filed: July 30, 2008
    Publication date: May 28, 2009
    Inventors: Heike PETRUL, Andreas Menrad, Jorg Willuda, Dieter Zopf, Jens Glienke, Josef Prassler, Andreas Popp, Stefan Steidl, Catrin Pracht
  • Publication number: 20090081207
    Abstract: The present invention relates to recombinant human or humanized polypeptides which bind to ?5?1 integrin with high affinity and blocking function. Further, diagnostic and pharmaceutic applications of the potypeptides are disclosed.
    Type: Application
    Filed: May 23, 2007
    Publication date: March 26, 2009
    Inventors: ANDREAS MENRAD, JOERG WILLUDA, KLAUS BOSSLET, DIETER ZOPF, HEIKE PETRUL, STEFAN STEIDL, JOSEF PRASSLER, CORINNE PETIT-FRERE